FDA Bravecto Warning – Four Key Facts

FDA Four Key Facts

1. “The FDA-approved drugs in this class are Bravecto, Credelio, Nexgard and Simparica. These products are approved for the treatment and prevention of flea infestations, and the treatment and control of tick infestations” – In clinic we use and will continue to offer Bravecto and Simparica and in the past have offered Nexgard, all without complication.

2. “Veterinarians should use their specialized training to review their patients’ medical histories and determine, in consultation with pet owners, whether a product in the isoxazoline class is appropriate for the pet” – Every pet is different and requires different considerations when using any medication, an increased awareness of this side effect is the goal of the FDA in order to better protect pets.

3. “working with Canadian manufacturers of drugs belonging to the isoxazoline class to include new labelling information that neurological adverse events have been reported in animals receiving this class of drug.” – These drugs have been used for a number of years already, the goal of the FDA is the improve labeling to include this noted adverse effect.

4. “The FDA considers products in the isoxazoline class to be safe and effective for dogs and cats but is providing this information so that pet owners and veterinarians can take it into consideration when choosing flea and tick products for their pets.” – The bottom line here is that the FDA still considers these products safe for use in pets and therefore are simply changing labeling vs. removing product from the market.

For more information visit Animal Health Literacy | FDA